Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02168036|
Recruitment Status : Terminated (Study was terminated due to lack of funding.)
First Posted : June 19, 2014
Last Update Posted : December 26, 2017
|Condition or disease|
|Lung Disease Inflammation Lung Cancer Sarcoidosis|
|Study Type :||Observational|
|Actual Enrollment :||56 participants|
|Official Title:||Evaluation of the Mediastinal Lymph Nodes With Endobronchial-Guided Transbronchial Needle Aspiration in Individuals With Lung Diseases|
|Actual Study Start Date :||August 16, 2011|
|Actual Primary Completion Date :||February 6, 2017|
|Actual Study Completion Date :||February 16, 2017|
Patients with lung disease
General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
- Evidence that is consistent with lung disease and presentation of enlarged mediastinal lymph nodes [ Time Frame: 24 Hours ]Bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02168036
|United States, New York|
|Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine|
|New York, New York, United States, 10021|
|Principal Investigator:||Ben-Gary Harvey, MD||Weill Medical College of Cornell University|